This excerpt taken from the THRX 8-K filed Oct 27, 2008.
Disposition and outcomes
· A total of 1532 individuals were randomized to receive study medication and 1503 received at least 1 dose of study medication (Figure 1).
· In the combined CE population of ATTAIN, the proportions of severely ill patients and older patients (>65 years) were mostly balanced between treatment groups, although more patients in the telavancin group had ALI or ARDS (Table 1).
· The cure rates obtained with telavancin were comparable to those achieved with conventional therapy across all severity subgroups. The cure rates were numerically higher in the APACHE II >20, ALI or ARDS, bacteremia, and age >65 years severity subgroups (Figure 2).